EverSource Wealth Advisors’s Rigel Pharmaceuticals RIGL Stock Holding History

EverSource Wealth Advisors’s Portfolio RIGL Stock Details RIGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$5.89K	Buy	218 +191	+707%	+$6.42K	﹤0.01%	3186
2025 Q4	$1.16K	Buy	+27	New	+$1.02K	﹤0.01%	3671
2025 Q2	–	Sell	-79	Closed	-$1.42K	–	4343
2025 Q1	$1.42K	Buy	79 +16	+25%	+$325	﹤0.01%	3087
2024 Q4	$1.06K	Hold	63	–	–	﹤0.01%	2945
2024 Q3	$1.02K	Hold	63	–	–	﹤0.01%	2725
2024 Q2	$667	Buy	+63	New	+$659	﹤0.01%	2823
2022 Q2	–	Sell	-387	Closed	-$11K	–	1861
2022 Q1	$11K	Buy	+387	New	+$10.5K	﹤0.01%	942

Other funds holding RIGL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

EverSource Wealth Advisors's RIGL Position: Q1 2026 in Review

EverSource Wealth Advisors increased its Rigel Pharmaceuticals (RIGL) stake by 707% in Q1 2026, buying an estimated $6.42K and bringing the position to 218 shares worth $5.89K. The position accounts for ﹤0.01% of the portfolio, ranked #3186.

EverSource Wealth Advisors first reported a position in RIGL in Q1 2022 and has held it in 7 quarters since. The position peaked at $11K in Q1 2022. 159 funds tracked by Wall St. Rank hold RIGL as of Q1 2026.

EverSource Wealth Advisors held 218 shares of Rigel Pharmaceuticals worth $5.89K as of Q1 2026.
EverSource Wealth Advisors bought 191 Rigel Pharmaceuticals shares in Q1 2026, an estimated $6.42K.
Rigel Pharmaceuticals made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q1 2026, its #3186 holding.
EverSource Wealth Advisors first reported a position in Rigel Pharmaceuticals in Q1 2022 and has held it in 7 quarters since.
EverSource Wealth Advisors's Rigel Pharmaceuticals position peaked at $11K in Q1 2022.
159 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q1 2026.

Based on EverSource Wealth Advisors's 13F filing for Q1 2026, filed 14 May 2026.